Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (Nasdaq:JAGX) announced that enrollment in its pivotal Phase 3 OnTarget clinical trial of crofelemer has surpassed 90%, with completion expected by mid-Q2 2023. This trial aims to assess the effectiveness of crofelemer in preventing diarrhea in adult cancer patients undergoing targeted therapy. The company’s current cash position stands at approximately $15.3 million. The OnTarget trial, now expanded to include sites in Eastern Europe, Argentina, and Taiwan, is crucial in demonstrating that chronic diarrhea affects patient adherence to cancer therapies. The trial evaluates crofelemer’s unique mechanism of action, targeting chloride ion channels in the gastrointestinal tract.
Jaguar Health (NASDAQ:JAGX) announced on April 6, 2023, its ongoing efforts to identify potential illegal naked short selling activities affecting its stock. The company has engaged Shareholder Intelligence Services to uncover trading anomalies and ensure compliance with FINRA and SEC regulations. Preliminary findings have shown slight trade imbalances meriting further investigation. Jaguar aims to safeguard shareholder interests and enhance shareholder value through this initiative.
ShareIntel's proprietary platform identifies markers of illegal short selling, assisting companies in ensuring true price discovery. Jaguar intends to keep the market updated on any material findings from this ongoing analysis.
Jaguar Health, Inc. (JAGX) announced its participation at the Veterinary Cancer Society Collaborative Conference from April 19-22, 2023, promoting Canalevia-CA1, the first FDA conditionally approved treatment for chemotherapy-induced diarrhea (CID) in dogs. As of December 2022, the FDA expanded the annual treatment capacity from 70,000 to 80,000 dogs, enhancing the market potential for Canalevia-CA1. The drug is available through major U.S. veterinary distributors, reflecting an ongoing commitment to address significant unmet needs among veterinarians treating cancer patients.
Jaguar Health reported a substantial growth in prescription product net revenue, totaling $11.9 million for the year ending December 31, 2022, marking a 178.7% increase from $4.3 million in 2021. The fourth quarter of 2022 alone saw revenues of approximately $3.3 million, up 3.4% from the previous quarter. As of March 24, 2023, the company had a cash position of $15.3 million. Key initiatives include progressing through 80% enrollment in the Phase 3 OnTarget trial for crofelemer aimed at cancer therapy-related diarrhea, and plans for additional investigator-initiated studies in 2023. The investor webcast on March 27 will further detail these updates.
Jaguar Health, Inc. (NASDAQ:JAGX) has announced a change in the timing of its investor webcast, now scheduled for March 27, 2023 at 8:00 AM EDT, to discuss the fourth-quarter 2022 financial results and corporate updates. The company plans to file its Annual Report on March 24, 2023, for the fiscal year ended December 31, 2022. Jaguar focuses on developing plant-based prescription medications for gastrointestinal distress in humans and animals. Its subsidiary, Napo Pharmaceuticals, is conducting a pivotal Phase 3 trial for the drug crofelemer aimed at cancer patients experiencing diarrhea.
Jaguar Health (NASDAQ:JAGX) announced the appointment of Dr. Kelly Shanahan to its Scientific Advisory Board on March 23, 2023. Dr. Shanahan is a former clinician and a metastatic breast cancer patient advocate, bringing a unique perspective to the company's focus on cancer therapy-related diarrhea (CTD). She emphasized the importance of patient comfort and the development of crofelemer, a drug targeting CTD. The OnTarget Phase 3 clinical trial for crofelemer is expected to complete patient enrollment in Q2 2023, potentially paving the way for a significant advancement in supportive care for cancer patients.
Jaguar Health, Inc. (NASDAQ:JAGX) announces an investor webcast on March 27, 2023, at 8:30 AM EDT to discuss Q4 2022 financial results and corporate updates. The company will also file its Annual Report on March 24, 2023 for the fiscal year ending December 31, 2022. Jaguar Health specializes in developing plant-based medications for gastrointestinal distress, with a focus on its candidate, crofelemer, which is undergoing a Phase 3 clinical trial for cancer patients experiencing diarrhea.
Jaguar Health announced the development of an AI-powered web portal to assist U.S. healthcare professionals with patient access to Mytesi (crofelemer), its FDA-approved drug for noninfectious diarrhea in HIV/AIDS patients. The initiative aims to mitigate access and reimbursement issues, specifically the burdensome prior authorization process. A recent AMA survey indicates that 88% of physicians face challenges with prior authorizations, which often delays patient care. By leveraging AI technology, Jaguar hopes to streamline this process and improve medication adherence, ultimately enhancing patient outcomes without collecting any Protected Health Information.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
